DIRECTORS | SCIENTIFIC TEAM
Chris is the Managing Director of Zucero and its founding shareholder. A lawyer by trade, Chris has extensive experience in M&A, capital markets, commercialisation and corporate governance.
Chris is the Chairman of Luina Bio, one of Australia’s most experienced biopharmaceutical CMOs.
Chris has held various ASX, government and non-government board appointments.
Jitto is a Melbourne-based businessman with over 20 years of extensive experience in corporate restructuring, capital raising, listing and running of public companies on the ASX .
Jitto is currently Chairman of TBG Diagnostics Ltd (ASX: TDL) and Lanka Graphite (ASX: LGR). Previously, he was Chairman of Euro Petroleum Ltd, Fortis Mining Ltd, Greater Western Exploration Ltd, Medic Vision Ltd and ATOS Wellness Ltd.
Dr eli huberman
Dr Huberman has made a significant contribution to cancer research, cellular differentiation and adult stem cell research for over 40 years and has published over 200 scientific papers.
Eli is the founder, scientific director, and CEO of Novadrug LLC, a Chicago-based firm established in 2006 which is dedicated to development of antiviral drugs, including drugs to combat hemorrhagic viruses that cause Ebola and Marburg diseases.
DR keith Dredge
Chief Scientific Officer
Previously, Director of Drug Development at Progen Pharmaceuticals, Senior Manager at TetraQ, Research Fellow at UQ (Australia) & SGUL (UK). CEO at Paragen Bio Ltd. Authored over 40 scientific articles including first publications on Celgene’s immunomodulatory drugs Revlimid® & Pomalyst®. Member of AACR, ASCO & SITC. BSc (Toxicology), PhD (Pharmacology).
CHIEF REGULATORY OFFICER
Regulatory consultant. Previously, Director of Clinical Development at Progen Pharmaceuticals, Director of Clinical Operations at Constella Group & Senior Project Manager at Origin Pharmaceutical Services. MMSc. (Drug Development) & BSc. (Chemistry).
EDWARD HAMMOND Phd
HEAD OF BIOLOGY
A co-inventor on the pixatimod original patent and author of over 30 publications. Previously, senior biochemist at Progen Pharmaceuticals, Research Scientist at the University of Maryland (USA), University of Melbourne (Australia). Edward has a BSc (Hons) from James Cook University (Australia), a PhD from the University of Melbourne.
PAUL HANDLEY Phd
Head of chemistry
A co-inventor on the original pixatimod patent. Over 17 years’ experience in drug discovery and early-stage drug development. Previously, at Progen Pharmaceuticals, Evotec Ltd (UK) and manufacturing of veterinary APIs at Research Directions Pty Ltd. Paul has a PhD in Chemistry (Natural Products) from the University of Queensland .